These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Clin Infect Dis; 2001 Apr 01; 32(7):1090-4. PubMed ID: 11264038 [Abstract] [Full Text] [Related]
9. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes. Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H. J Trop Pediatr; 2011 Oct 01; 57(5):347-51. PubMed ID: 21078605 [Abstract] [Full Text] [Related]
10. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. Weinberg A, Gona P, Nachman SA, Defechereux P, Yogev R, Hughes W, Wara D, Spector SA, Read J, Elgie C, Cooper M, Dankner W, Pediatric AIDS Clinical Trials Group 1008 Team. J Infect Dis; 2006 Jan 15; 193(2):302-11. PubMed ID: 16362896 [Abstract] [Full Text] [Related]
11. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Borte S, Liebert UG, Borte M, Sack U. Rheumatology (Oxford); 2009 Feb 15; 48(2):144-8. PubMed ID: 19074187 [Abstract] [Full Text] [Related]
12. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy. Sultana R, Rahman MM, Hassan Z, Hassan MS. Scand J Immunol; 2006 Dec 15; 64(6):684-9. PubMed ID: 17083626 [Abstract] [Full Text] [Related]
16. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Abzug MJ, Song LY, Fenton T, Nachman SA, Levin MJ, Rosenblatt HM, Pelton SI, Borkowsky W, Edwards KM, Peters J, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 Protocol Team. Pediatrics; 2007 Nov 01; 120(5):e1190-202. PubMed ID: 17938165 [Abstract] [Full Text] [Related]
17. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand. Chaiwarith R, Praparattanapan J, Nuket K, Kotarathitithum W, Supparatpinyo K. BMC Infect Dis; 2016 Apr 30; 16():190. PubMed ID: 27138005 [Abstract] [Full Text] [Related]
18. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P. Vaccine; 2009 Jan 14; 27(3):446-53. PubMed ID: 19007835 [Abstract] [Full Text] [Related]
19. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L, Cesaro S. Cancer; 2004 Aug 01; 101(3):635-41. PubMed ID: 15274078 [Abstract] [Full Text] [Related]
20. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Lao-araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Vaccine; 2007 Jul 20; 25(29):5324-9. PubMed ID: 17566615 [Abstract] [Full Text] [Related] Page: [Next] [New Search]